Corpus ID: 2811480

4-Demethylpenclomedine, an antitumor-active, potentially nonneurotoxic metabolite of penclomedine.

  title={4-Demethylpenclomedine, an antitumor-active, potentially nonneurotoxic metabolite of penclomedine.},
  author={W. Waud and A. Tiwari and S. Schmid and T. W. Shih and J. M. Strong and N. Hartman and S. O'Reilly and R. Struck},
  journal={Cancer research},
  volume={57 5},
  • W. Waud, A. Tiwari, +5 authors R. Struck
  • Published 1997
  • Biology, Medicine
  • Cancer research
  • Penclomedine [3,5-dichloro-4,6-dimethoxy-2-(trichloromethyl)pyridine], an antitumor agent, is currently in Phase I clinical trials and is believed to be a prodrug. In these studies, cerebellar effects have been dose limiting. Previous studies identified 4-demethylpenclomedine (4-DM-PEN) as the major plasma metabolite in rodents and humans. 4-DM-PEN was demonstrated to be an antitumor-active metabolite of penclomedine in vivo when evaluated against the penclomedine-sensitive MX-1 human breast… CONTINUE READING
    9 Citations
    The in vitro metabolism of penclomedine in mouse, rat, and human systems.
    • 1
    • PDF
    Synthesis and Anti-cancer Activity of Some Novel 5-Azacytosine Nucleosides
    • 5


    Murine and human in vivo penclomedine metabolism.
    • 11
    • PDF
    Tissue and tumor distribution of C-penclomedine in rats.
    • S. O'Reilly, N. Hartman, +6 authors E. Rowinsky
    • Biology, Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 1996
    • 8
    • PDF
    Neuroanatomic studies of the cerebellar effects of penclomedine
    • Proc. Am. Assoc. Cancer Res
    • 1996
    Phase I and pharmacokinetic trial of penclomedine
    • Proc. Am. Assoc. Cancer Res
    • 1995
    Phase I and pharmacologic studies of penclomedine, a novel alkylating agent with prominent preclinical activity in breast cancer
    • Proc. Am. Soc. Clin. Oncol
    • 1995
    Cancer Rca
    • Cancer Rca
    • 1909